News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Peanut Allergy Treatment Works Long Term
Jef Akst | Aug 17, 2017
Four years after taking a probiotic and peanut protein for 18 months, two-thirds of children in a small clinical trial can eat peanuts with no health issues.
Immunotherapy Promising for Diabetes: Study
Aggie Mika | Aug 9, 2017
A small clinical trial demonstrates that peptide immunotherapy can halt the progression of early-stage type 1 diabetes.
Stem Cells Seek Out Tumors Based on Stiffness
Shawna Williams | Jul 26, 2017
The technique, demonstrated in mice using engineered mesenchymal stem cells, has potential for both diagnosis and treatment.
FDA Votes Yes on CAR T-Cell Therapy
Aggie Mika | Jul 13, 2017
A Food and Drug Administration advisory panel unanimously calls for agency approval of the cell therapy for the treatment of resistant leukemia.
Personalized Cancer Vaccines Show Promise for Melanoma
Jef Akst | Jul 6, 2017
In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Rare T Cells Fight Cancer
Jef Akst | May 1, 2017
A new approach to immunotherapy finds that the immune-cell clonotypes that come to the rescue start out at very low frequencies.
Gel Scaffolds for Delivery of Immunotherapies
Rachel Berkowitz | Apr 1, 2017
Using biocompatible polymers to carry cancer immune therapies directly to the tumor
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.